Blood pressure medication recalled over fears of 'microbial contamination'
A blood pressure medication has been recalled from suppliers due to possible “microbial contamination”. Amlodipine is a ...
Medscape4d
The Pathophysiological and Pharmacological Basis of Current Drug Treatment of Migraine Headache
Other potential PAM agents without class 1 data include levetiracetam, zonisamide, cyproheptadine, verapamil, amlodipine ... Axert® 6.25, 12.5 mg tablets 12.5 mg p.o.; can be repeated once ...
Medscape20d
Evidence-based Review of the Black-box Warning for Droperidol
Droperidol was a first-line, highly effective agent for the treatment of PONV for over 30 years. It has the most postmarketing surveillance data of any of the currently used antiemetic agents.
Healio1d
FDA approves Evrysdi tablets for spinal muscular atrophy
The FDA has approved Evrysdi in tablet form for patients with spinal muscular atrophy aged 2 years and older who weigh more ...
Contract Pharma2d
FDA Greenlights Roche’s Evrysdi Tablet
New 5mg tablet offers the same established efficacy and safety as the Evrysdi oral solution for individuals living with spinal muscular atrophy.
Monthly Prescribing Reference3d
New Tablet Formulation of SMA Therapy Evrysdi Gets FDA Approval
The tablet formulation can either be swallowed whole or dispersed in a teaspoon of filtered (non-chlorinated) water.
The American Journal of Managed Care3d
Risdiplam Tablet for Spinal Muscular Atrophy Receives FDA Approval
The 5 mg risdiplam tablet provides the same efficacy and safety for spinal muscular atrophy as the currently available oral ...
Roche announces FDA approves Evrysdi tablet to treat SMA
Roche (RHHBY) announced that the Food and Drug Administration has approved a New Drug Application for an Evrysdi tablet for people living with ...
BioSpace1d
Roche’s Evrysdi Becomes First Pill Cleared for Spinal Muscular Atrophy
The FDA on Wednesday approved the industry’s first-ever tablet treatment for spinal muscular atrophy— Roche ’s SMN2 splicing ...
FiercePharma3d
Roche scores FDA nod for Evrysdi tablets, bolstering convenience edge over rivals
Over the past nine years, patients with spinal muscular atrophy have seen the number of FDA-approved treatment options for ...
Joplin Globe3d
FDA Approves Genentech’s Evrysdi Tablet as First and Only Tablet for Spinal Muscular Atrophy (SMA)
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has approved a New Drug Application (NDA) for an Evrysdi ® ...